Dronabinol

Dronabinol oral solution contains alcohol and propylene glycol which produce disulfiram-like reactions. Discontinue disulfiram at least 14 days before starting dronabinol and do not administer within 7 days of completing treatment.

Dronabinol oral solution contains alcohol which produces disulfiram-like reactions when co-administered with metronidazole. Discontinue metronidazole at least 14 days before starting dronabinol and do not administer within 7 days of completing treatment.

CYP2C9 inhibitor may increase dronabinol systemic exposure and adverse reactions; monitor for increased dronabinol-related effects.

Highly protein-bound drug with narrow therapeutic index; dronabinol may displace amphotericin B from plasma proteins increasing free fraction. Monitor for adverse reactions.

Monitor for potentially increased dronabinol-related adverse reactions when dronabinol capsules are co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice).

Additive CNS effects (dizziness, confusion, sedation, somnolence) may occur when taken concomitantly with dronabinol.

Highly protein-bound drug with narrow therapeutic index; dronabinol may displace cyclosporine from plasma proteins increasing free fraction. Monitor for adverse reactions.

Monitor for potentially increased dronabinol-related adverse reactions when dronabinol capsules are co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice).

Monitor for potentially increased dronabinol-related adverse reactions when dronabinol capsules are co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice).

CYP3A4 inhibitor may increase dronabinol systemic exposure and adverse reactions; monitor for increased dronabinol-related effects.

Monitor for potentially increased dronabinol-related adverse reactions when dronabinol capsules are co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice).

Monitor for potentially increased dronabinol-related adverse reactions when dronabinol capsules are co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice).

Monitor for potentially increased dronabinol-related adverse reactions when dronabinol capsules are co-administered with inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) and inhibitors of CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice).

Highly protein-bound drug with narrow therapeutic index; dronabinol may displace warfarin from plasma proteins increasing free fraction. Monitor for adverse reactions.